Nalmefene: Intravenous safety and kinetics of a new opioid antagonist
The DOI matches its Crossref record.
Abstract
In a placebo-controlled, double-blind study we evaluated the safety and kinetics of a new narcotic antagonist, nalmefene, after 2, 6, 12, and 24 mg intravenous doses to healthy men. At each dose level four subjects received active drug and two received placebo. The drug was well tolerated at all dose levels with only mild and transient side effects, the most common of which was lightheadedness. The plasma concentration-time data were best fit with a triexponential equation, and the terminal elimination phase had a harmonic mean t1/2 of 8 to 9 hours. Only about 5% of the dose was excreted in the urine as intact nalmefene, with up to 60% excreted as nalmefene glucuronide. Although intersubject differences were noted, mean or dose-normalized mean kinetic parameters such as clearance, steady-state volume of distribution, terminal t1/2, and AUC showed no consistent trends related to increasing doses, indicating that nalmefene has linear pharmacokinetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343
Cannabinoids, opioids and eating behavior: The molecular face of hedonism?
Cota, D., Tschöp, M. H., Horvath, T. L., & Levine, A. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.10.004 · Cited by 330
Crain, S. M., & Shen, K.-F. (2000) · Pain · doi:10.1016/s0304-3959(99)00223-7 · Cited by 306
Opioid peptides and primary biliary cirrhosis
Thornton, J. R., & Losowsky, M. S. (1988) · BMJ · doi:10.1136/bmj.297.6662.1501 · Cited by 300
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C., & Cutler, R. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.719 · Cited by 271
Metadata
- Authors
- Dixon, R., Howes, J., Gentile, J., Hsu, H.-B., Hsiao, J., Garg, D., Weidler, D., Meyer, M., & Tuttle, R.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1986-01
- Volume
- 39
- Issue
- 1
- Pages
- 49-53
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1975183736
- Cited by
- 98
- References
- 0
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. https://app.cochat.ai/papers/10.1038/clpt.1986.9
- The paper
- Dixon, R., Howes, J., Gentile, J., Hsu, H.-B., Hsiao, J., Garg, D., Weidler, D., Meyer, M., & Tuttle, R. (1986). Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.1986.9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.